Acne Keloidalis Nuchae: Chronic Folliculitis with Keloidal Scarring of the Nape

Clinical Overview

Acne keloidalis nuchae (AKN), also termed folliculitis nuchae keloidalis or nuchal keloidosis, is a chronic, progressive inflammatory condition affecting the nape and posterior scalp, characterized by folliculitis leading to keloid formation and severe scarring alopecia. Despite the name containing "acne," AKN is actually a form of chronic folliculitis perpetuated by follicular occlusion, often exacerbated by close-cut hair or military haircuts creating inward-pointing hairs that perforate the follicle wall. The condition predominantly affects men of African descent (0.45-1% prevalence) and causes significant cosmetic and functional morbidity due to keloidal scarring. Management requires aggressive early intervention to prevent progression to severe scarring and hair loss.

Epidemiology

Acne keloidalis nuchae predominantly affects men aged 13-40 years, with peak incidence in 20s-30s. Striking racial predisposition: 0.45-1% prevalence in African American men compared to <0.1% in Caucasian men, attributed to higher keloid predisposition and follicular anatomy. Cases are rare in women. Geographic distribution correlates with military populations and populations where close-cut hair is culturally common. Associated conditions include folliculitis decalvans (scarring folliculitis of scalp), hidradenitis suppurativa, and pilonidal sinus disease (follicular occlusion syndrome) in 15-20% of patients. Early-stage disease presents in 40-50% of men with nape hair involvement within 3-5 years of initiating close-cut hairstyles.

Pathophysiology

Acne keloidalis nuchae results from follicular trauma and occlusion perpetuating chronic inflammation: (1) close-cut or razor-cut hairs, particularly military-style haircuts, create short stubbled hairs (1-3 mm) that curve back and perforate the follicle wall; (2) foreign body reaction from perforation triggers granulomatous inflammation; (3) chronic inflammation stimulates fibroblast activation and collagen overproduction characteristic of keloids (type I and III collagen accumulation); (4) defective apoptosis in fibroblasts prolongs cellular survival and collagen deposition; (5) TGF-β signaling abnormalities perpetuate myofibroblast differentiation. Genetic predisposition to keloid formation is particularly prominent in African ancestry populations (10-15% keloid prevalence compared to 0.5-3% in Caucasians), driven by differences in growth factor signaling. Secondary bacterial infection (S. aureus, C. acnes) perpetuates inflammation.

Clinical Presentation

Early-stage AKN presents with folliculitis: papules and pustules in the nuchal region (nape of neck) along the hairline and posterior scalp. Lesions are often pruritic and painful, particularly with hair manipulation or touching. Progressive disease develops keloidal features: firm, flesh-colored to hyperchromatic nodules enlarge beyond original follicle boundary (key feature distinguishing keloid from hypertrophic scar). Size ranges from 0.5-2 cm in early disease to 5+ cm in chronic untreated cases. Surface may show draining sinuses and purulent material. Advanced disease shows scarring alopecia (hair loss from keloid area) and contracture causing neck stiffness and functional impairment (difficulty with neck extension, collar irritation). Associated symptoms: pain (40-50%), pruritis (30-40%), drainage (50%), and psychological distress from visible disfigurement.

Diagnosis

Clinical diagnosis is based on location (nape and lower posterior scalp), characteristic keloidal nodules extending beyond follicle boundaries, and chronic course. Dermoscopy shows keloidal collagen with dilated follicular openings. Biopsy shows chronic folliculitis with fibrosis extending beyond follicle (distinguishing from hypertrophic scar which remains within follicular boundaries), granulomatous inflammation, and keloid-pattern collagen deposition (thick bundles of collagen). Histology confirms diagnosis and rules out other scarring folliculitis (folliculitis decalvans, which shows complete follicle destruction) and malignancy. Microbiology of purulent material often shows S. aureus and C. acnes. Imaging is not routinely needed; ultrasound or MRI can assess depth of keloid involvement if surgical planning is needed.

Treatment Algorithm

Hair Management (Prevention): First-line intervention preventing progression or recurrence. Strict avoidance of close-cut, razor-cut, or clipper-cut hair is essential. Recommend growing hair to ≥6 mm length or longer, eliminating short stubble that causes follicular perforation. Electric clippers with longer guards (≥6 mm) or scissors preferable to razors. Chemical depilation (hair removal cream) can be considered as alternative to cutting. Some patients benefit from hair removal entirely (complete baldness eliminates trauma), though cosmetically unacceptable to most.

Intralesional Corticosteroids: Triamcinolone acetonide 40 mg/mL injected monthly into keloid tissue (0.1-0.2 mL per injection point at 1 cm intervals through lesion). Series of 4-6 monthly injections achieves 60-70% improvement in erythema and size reduction. Particularly effective in early-stage disease (<1-2 years duration). Mechanism: inhibits TGF-β signaling and fibroblast proliferation. Complications include local atrophy (<5%) with proper technique.

Systemic Antibiotics: Tetracyclines (doxycycline 100 mg daily or minocycline 100 mg daily) for 3-6 months reduce inflammation through anti-inflammatory mechanisms (TNF-α suppression, IL-6 reduction) independent of antimicrobial effect. Achieves 40-50% improvement in inflammatory lesions. Can combine with intralesional steroids for additive benefit. Limit courses to 6-8 months to prevent resistance.

Topical Therapies: Potent topical corticosteroids under occlusion (clobetasol propionate 0.05% ointment with occlusion) show modest benefit (30-40% improvement) in early lesions over 8-12 weeks. Topical retinoids and silicone-based scar prevention products show limited benefit. More useful as adjunctive therapy.

Surgical Excision: Indicated for established keloids refractory to medical therapy or causing functional impairment. Surgical approaches: (1) simple excision with primary closure achieves 40-50% recurrence rate if performed alone; (2) excision with reconstruction (split-thickness skin graft or advancement flap) reduces recurrence to 10-20%; (3) excision combined with adjunctive intralesional steroid injection (triamcinolone 40 mg/mL at surgery and monthly for 6 months postoperatively) reduces recurrence to 5-10%. Surgical approach depends on keloid size and depth. Complete excision with high-quality closure technique is essential for optimal outcomes.

Radiation Therapy: Post-surgical radiation (brachytherapy with Iridium-192 or external beam radiation) reduces recurrence to <10% when combined with excision, though long-term safety concerns (malignancy risk) and cosmetic effects (telangectasia, dyspigmentation) limit use to refractory cases. Reserved for very large or recurrent keloids after failed surgical excision.

Prognosis

Without intervention, acne keloidalis nuchae is progressive with 60-80% worsening over 5 years. Early recognition and prevention (hair length management) halts or prevents progression in 70-80% of cases. With intralesional steroids alone: 60-70% achieve improvement in appearance over 4-6 months, though complete clearance is rare. Surgical excision with proper technique and adjunctive therapy achieves best cosmetic outcomes with 85-90% of patients satisfied with results. Recurrence post-surgery occurs in 5-20% depending on technique and adjuvant therapy. Scarring alopecia is often permanent even with treatment if hair follicles are destroyed. Psychological improvement parallels visible improvement, with depression and social withdrawal significantly improving once disease is controlled.

When to See a Dermatologist

Early referral is recommended for new nuchal folliculitis to prevent progression to keloids. Dermatologists can perform intralesional injections and monitor disease progression. Refer to dermatologic surgery for established keloids requiring excision, particularly if simple excision has failed previously.

Frequently Asked Questions

Q: Is acne keloidalis nuchae contagious?
A: No, acne keloidalis nuchae is not contagious. It is a chronic inflammatory condition caused by follicular trauma from close-cut hair, not an infection or disease that spreads to others.

Q: Will growing my hair out help?
A: Yes, absolutely. Growing hair to ≥6 mm length is the most important preventive step. By avoiding close-cut hair, you eliminate the stubble that causes follicular trauma and perpetuates the condition. Many patients find that simply changing their hairstyle to longer hair dramatically improves the condition.

Q: Is surgical removal the only cure?
A: Not necessarily. Early intervention with hair management and intralesional steroid injections can halt or reverse early-stage disease. Surgery is most beneficial for established keloids refractory to medical therapy. Starting treatment early when lesions are small achieves best outcomes without surgery.

Q: Will my hair grow back after keloid treatment?
A: If keloids form and destroy hair follicles, hair may not regrow in those areas even after treatment. However, if treatment prevents keloid formation or catches disease early, follicles may survive and hair can regrow. Prompt intervention is important to preserve hair follicles.

References